CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $512,430 | +52.7% | 18,600 | 0.0% | 0.10% | +41.9% |
| Q2 2023 | $335,544 | -1.4% | 18,600 | 0.0% | 0.07% | -42.6% |
| Q4 2022 | $340,380 | -3.6% | 18,600 | 0.0% | 0.13% | +50.0% |
| Q3 2022 | $353,000 | +0.6% | 18,600 | 0.0% | 0.09% | +11.7% |
| Q2 2022 | $351,000 | -14.0% | 18,600 | 0.0% | 0.08% | -2.5% |
| Q1 2022 | $408,000 | -22.0% | 18,600 | 0.0% | 0.08% | -12.2% |
| Q4 2021 | $523,000 | +42.1% | 18,600 | 0.0% | 0.09% | +34.3% |
| Q3 2021 | $368,000 | -5.2% | 18,600 | 0.0% | 0.07% | -10.7% |
| Q2 2021 | $388,000 | +26.8% | 18,600 | 0.0% | 0.08% | +15.4% |
| Q1 2021 | $306,000 | +16.3% | 18,600 | 0.0% | 0.06% | +8.3% |
| Q4 2020 | $263,000 | -15.4% | 18,600 | 0.0% | 0.06% | -29.4% |
| Q3 2020 | $311,000 | – | 18,600 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 3,375,169 | $84,379,000 | 7.91% |
| RA Capital Management | 1,875,209 | $46,880,000 | 2.52% |
| Perceptive Advisors | 2,587,953 | $64,698,000 | 1.48% |
| New Leaf Venture Partners, L.L.C. | 167,700 | $4,193,000 | 1.12% |
| Orbimed Advisors | 2,039,282 | $50,982,000 | 0.79% |
| Eventide Asset Management | 803,839 | $20,096,000 | 0.61% |
| Novo Holdings A/S | 135,009 | $3,375,000 | 0.47% |
| Opaleye Management Inc. | 36,000 | $900,000 | 0.27% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 490,000 | $12,250,000 | 0.03% |
| Baker Brothers Advisors | 132,985 | $3,325,000 | 0.02% |